MX2016002370A - Agente terapeutico para dislipidemia. - Google Patents
Agente terapeutico para dislipidemia.Info
- Publication number
- MX2016002370A MX2016002370A MX2016002370A MX2016002370A MX2016002370A MX 2016002370 A MX2016002370 A MX 2016002370A MX 2016002370 A MX2016002370 A MX 2016002370A MX 2016002370 A MX2016002370 A MX 2016002370A MX 2016002370 A MX2016002370 A MX 2016002370A
- Authority
- MX
- Mexico
- Prior art keywords
- drug composition
- dyslipidemia
- therapeutic agent
- omega
- preventing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta invención proporciona una composición combinada de fármacos y un uso combinado de los productos farmacéuticos para la prevención y/o tratamiento de estados de dislipidemia, tales como hipercolesterolemia LDL, en los mamíferos, incluyendo seres humanos. Esta invención se refiere a una composición de fármaco para prevenir y/o tratar la dislipidemia y similares, que comprende la siguiente composición de fármaco: ácido (R)-2-[3-[[N-(benzoxazol-2-il)-N-3-(4-metoxifenoxi)propil]aminome til]fenoxi]butírico, una sal del mismo, o un solvato del mismo; y un ácido graso omega-3 o un derivado de éster de un ácido graso ?-3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013176364 | 2013-08-28 | ||
| PCT/JP2014/072380 WO2015030033A1 (ja) | 2013-08-28 | 2014-08-27 | 脂質異常症治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016002370A true MX2016002370A (es) | 2016-05-31 |
Family
ID=52586585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016002370A MX2016002370A (es) | 2013-08-28 | 2014-08-27 | Agente terapeutico para dislipidemia. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20160206598A1 (es) |
| EP (2) | EP3040071A4 (es) |
| JP (2) | JPWO2015030033A1 (es) |
| KR (3) | KR20230050472A (es) |
| CN (2) | CN110327331B (es) |
| AU (1) | AU2014312931B2 (es) |
| CA (1) | CA2919817C (es) |
| HK (1) | HK1219662A1 (es) |
| IL (1) | IL244106B (es) |
| MX (1) | MX2016002370A (es) |
| MY (1) | MY182468A (es) |
| TW (1) | TWI718089B (es) |
| WO (1) | WO2015030033A1 (es) |
| ZA (1) | ZA201601152B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI691331B (zh) * | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
| US20220096443A1 (en) * | 2018-12-27 | 2022-03-31 | Kowa Company, Ltd. | Pharmaceutical composition |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003043997A1 (en) | 2001-11-15 | 2003-05-30 | Eli Lilly And Company | Peroxisome proliferator activated receptor alpha agonists |
| US6987118B2 (en) | 2003-05-21 | 2006-01-17 | Pfizer Inc. | Tetrahydroisoquinoline derivatives as PPAR-alpha activators |
| JPWO2005009942A1 (ja) | 2003-07-28 | 2006-09-07 | 杏林製薬株式会社 | 光学活性置換フェニルプロピオン酸誘導体 |
| PL1661890T3 (pl) | 2003-09-03 | 2011-06-30 | Kowa Co | Związek aktywujący PPAR oraz kompozycja farmaceutyczna zawierająca ten związek |
| DE102004016845A1 (de) | 2004-04-07 | 2005-10-27 | Bayer Healthcare Ag | Phenylthioessigsäure-Derivate und ihre Verwendung |
| ATE488236T1 (de) | 2004-09-16 | 2010-12-15 | Merck Sharp & Dohme | Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen |
| TWI359810B (en) | 2004-11-04 | 2012-03-11 | Mitsubishi Tanabe Pharma Corp | Carboxylic acid derivative containing thiazole rin |
| CN101098690A (zh) * | 2004-12-06 | 2008-01-02 | 瑞莱恩特医药品有限公司 | 用于血脂治疗的ω-3脂肪酸和脂血异常剂 |
| US7795291B2 (en) | 2006-07-07 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method |
| TWI407955B (zh) * | 2007-03-29 | 2013-09-11 | Kowa Co | 高脂血症之預防及／或治療劑 |
| WO2009047240A1 (en) | 2007-10-09 | 2009-04-16 | Smithkline Beecham Corporation | Indole derivatives useful as ppar activators |
| DE102007061757A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung |
| US20100081694A1 (en) * | 2008-09-30 | 2010-04-01 | Epax As | Composition comprising at least one ppar agonist and a lipid component |
-
2014
- 2014-08-27 CN CN201910559476.1A patent/CN110327331B/zh active Active
- 2014-08-27 TW TW103129484A patent/TWI718089B/zh not_active IP Right Cessation
- 2014-08-27 MY MYPI2016700544A patent/MY182468A/en unknown
- 2014-08-27 KR KR1020237011090A patent/KR20230050472A/ko not_active Application Discontinuation
- 2014-08-27 WO PCT/JP2014/072380 patent/WO2015030033A1/ja active Application Filing
- 2014-08-27 KR KR1020217026669A patent/KR20210107168A/ko not_active IP Right Cessation
- 2014-08-27 CN CN201480033806.9A patent/CN105307653B/zh active Active
- 2014-08-27 MX MX2016002370A patent/MX2016002370A/es unknown
- 2014-08-27 US US14/913,064 patent/US20160206598A1/en not_active Abandoned
- 2014-08-27 AU AU2014312931A patent/AU2014312931B2/en active Active
- 2014-08-27 CA CA2919817A patent/CA2919817C/en active Active
- 2014-08-27 KR KR1020157035948A patent/KR20160045042A/ko active Application Filing
- 2014-08-27 EP EP14841322.2A patent/EP3040071A4/en not_active Ceased
- 2014-08-27 EP EP21192564.9A patent/EP3939586A1/en active Pending
- 2014-08-27 JP JP2015534249A patent/JPWO2015030033A1/ja active Pending
-
2016
- 2016-02-14 IL IL244106A patent/IL244106B/en active IP Right Grant
- 2016-02-19 ZA ZA2016/01152A patent/ZA201601152B/en unknown
- 2016-07-05 HK HK16107763.2A patent/HK1219662A1/zh unknown
-
2018
- 2018-09-21 JP JP2018176777A patent/JP6650006B2/ja active Active
- 2018-10-03 US US16/150,514 patent/US20190030005A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2919817A1 (en) | 2015-03-05 |
| JP2018197273A (ja) | 2018-12-13 |
| TW201542205A (zh) | 2015-11-16 |
| TWI718089B (zh) | 2021-02-11 |
| EP3040071A4 (en) | 2017-04-12 |
| US20160206598A1 (en) | 2016-07-21 |
| IL244106B (en) | 2020-11-30 |
| CN105307653B (zh) | 2019-07-26 |
| MY182468A (en) | 2021-01-25 |
| HK1219662A1 (zh) | 2017-04-13 |
| AU2014312931A1 (en) | 2016-02-18 |
| EP3939586A1 (en) | 2022-01-19 |
| WO2015030033A1 (ja) | 2015-03-05 |
| CN105307653A (zh) | 2016-02-03 |
| KR20160045042A (ko) | 2016-04-26 |
| CN110327331B (zh) | 2022-04-26 |
| IL244106A0 (en) | 2016-04-21 |
| JP6650006B2 (ja) | 2020-02-19 |
| EP3040071A1 (en) | 2016-07-06 |
| KR20210107168A (ko) | 2021-08-31 |
| CN110327331A (zh) | 2019-10-15 |
| JPWO2015030033A1 (ja) | 2017-03-02 |
| AU2014312931B2 (en) | 2019-09-19 |
| ZA201601152B (en) | 2018-05-30 |
| KR20230050472A (ko) | 2023-04-14 |
| US20190030005A1 (en) | 2019-01-31 |
| CA2919817C (en) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ716421A (en) | Drug for treatment of nonalcoholic fatty liver disease | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| BR112017003546A2 (pt) | amidas heterocíclicas como inibidores de rip1 quinase como medicamentos | |
| WO2015031564A3 (en) | Substituted-1h-benzo[d]imidazole compounds as lysine-specific demethylase 1 (lsd1 ) inhibitors | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| PH12017501095A1 (en) | Piperidine derivatives as hdac1/2 inhibitors | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| WO2014121137A3 (en) | Compositions and methods for the treatment of neurodegenerative and other diseases | |
| EP3138834A4 (en) | Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient | |
| MX2016005437A (es) | Derivados de n-(1-hidroxi-3-(pirrolidinil)propan-2-il)pirrolidin-3 -carboxamida como inhibidores de glucosilceramida sintasa. | |
| WO2015066302A3 (en) | Compositions, methods of use, and methods of treatment | |
| ZA202003281B (en) | Heterocycle substituted pyridine derivative antifungal agents | |
| EP3352750A4 (en) | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient | |
| TR201907274T4 (tr) | Kurutulmuş Biyoselüloz Üretimi İçin Yöntem. | |
| EA033769B9 (ru) | Отселектированный амид -гидроксимасляной кислоты и его применения при лечении злоупотребления алкоголем | |
| EP3311817A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF EYES DISEASES WITH IMATINIB AS AN ACTIVE SUBSTANCE | |
| MX2016002370A (es) | Agente terapeutico para dislipidemia. | |
| EP3167893A4 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for preventing and treating retinal diseases | |
| WO2016069542A3 (en) | Lactone compounds and methods of making and using same | |
| WO2016030899A8 (en) | Methods of treating amyotrophic lateral scleroses | |
| WO2013033602A3 (en) | Fatty acid amides, compositions and methods of use | |
| WO2016144704A3 (en) | Heterocyclic autotaxin inhibitor compounds | |
| HK1216233A1 (zh) | 含有四氫吡喃基氨基環戊基羰基四氫吡啶並吡啶衍生物作為有效成分的眼後段疾病的預防或治療劑 | |
| PH12020500472A1 (en) | Autotaxin inhibitor compounds |